On January 27, 2021 LegoChem Biosciences reported that it has entered into a worldwide license agreement with Pyxis Oncology for the development and commercialization of LCB67, an innovative antibody-drug-conjugate (ADC) candidate (Press release, LegoChem Biosciences, JAN 27, 2021, View Source;sc_seq=413 [SID1234628151]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Pyxis will make an upfront payment of $9.5 million plus the cost LCB has spent for clinical trial material production upon its completion next year. LCB is eligible to receive milestone payments of up to $284.5 million as well as royalties on commercial sales. In addition, LCB has a right to exercise an option for obtaining Pyxis’ equity and revenue sharing upon Pyxis’ sublicense agreement with third party companies. Payments from Pyxis though this agreement will be shared with Y-Biologics based on pre-agreed terms.
The licensed ADC program (LCB67, a DLK1-targeting ADC) is an Investigational Drug Candidate that has been generated through combining LCB’s next-generation ADC platform with anti-DLK1 antibody, which was in-licensed from Y-Biologics. DLK-1 is a novel cancer target which is associated with various solid tumors including liver and small cell lung cancers. Pyxis plans to advance this program to clinical trials for progressive solid cancers with high medical unmet needs.
"The members of Pyxis are industry-leading US experts who have successfully led the development of innovative new drugs, and we have a strong confidence that Pyxis will enter LCB67 into clinical trials in the most efficient manner." said Dr. Yong-Zu Kim, CEO and President of LCB.
Dr. Lara Sullivan, CEO of Pyxis, added, "LCB67 has significant potential to be an effective treatment for a range of indications. LegoChem’s unique ADC platform drastically improves upon existing technology to provide a highly stable therapeutic with unparalleled manufacturing consistency. Our partnership with LegoChem is crucial to advance this next generation ADC to the clinic and ultimately bring a new potential treatment option to patients."
This agreement is the second case of LCB’s ADCs generated through successful collaboration between Korean biotech companies, first being LCB71, an anti-ROR1 ADC which was co-developed by LCB and ABL BIO and licensed to CStone Pharmaceuticals last month. This is the 4th global licensing agreement of LCB’s ADCs this year only.